viewArix Bioscience PLC

Arix Bioscience investee company strengthens pipeline

The venture capital firm applauded the exclusive deal inked by Artios Pharma

Arix Bioscience PLC -
DDR is a network of cellular pathways that sense, signal and repair DNA lesion

Arix Bioscience PLC (LON:ARIX) said an investee company has “in-licensed” an ATR inhibitor programme from one of the world’s leading cancer centres and a venture capital firm.

Artios Pharma’s exclusive deal with The University of Texas MD Anderson Cancer Center and ShangPharma Innovation strengthens the company’s earlier-stage pipeline focused on the area of DNA damage response.

DDR is a network of cellular pathways that sense, signal and repair DNA lesions.

Surveillance proteins that monitor DNA integrity can activate cell cycle checkpoints and DNA repair pathways in response to DNA damage, to prevent the generation of potentially harmful mutations.

Arix investment director, Jonathan Tobin, who is also an Artios board member, said he was pleased to see the firm’s pipeline “continue to grow and mature”.  

“This deal, coupled with Artios’ significant expertise in this field, reinforces its position as the world leader in this exciting new space in oncology,” he added.

Quick facts: Arix Bioscience PLC

Price: 95 GBX

Market: LSE
Market Cap: £128.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...



Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read